Schredl M, Weber B, Braus D, Gattaz W F, Berger M, Riemann D, Heuser I
Central Institute of Mental Health, P.O. Box 122120, 68072, Mannheim, Germany.
Exp Gerontol. 2000 Mar;35(2):243-9. doi: 10.1016/s0531-5565(00)00077-2.
Previous research has shown that acetylcholinesterase inhibitors may affect REM sleep, however, results are inconclusive. From the present findings it is concluded that the effects of rivastigmine, a reversible acetycholinesterase inhibitor, on REM sleep are more pronounced in the elderly where we found REM latency to be significantly reduced. This may be explained by better bioavailability and/or by reduced stability of the circadian rhythmicity in elderly individuals. Because rivastigmine is used in the treatment of Alzheimer's disease, further research investigating the relationship between the REM enhancing properties of rivastigmine and cognitive functioning seems promising.
先前的研究表明，乙酰胆碱酯酶抑制剂可能会影响快速眼动睡眠，然而，结果尚无定论。从目前的研究结果可以得出结论，利伐斯的明（一种可逆性乙酰胆碱酯酶抑制剂）对快速眼动睡眠的影响在老年人中更为明显，我们发现老年人的快速眼动睡眠潜伏期显著缩短。这可能是由于老年人具有更好的生物利用度和/或昼夜节律稳定性降低所致。由于利伐斯的明用于治疗阿尔茨海默病，进一步研究利伐斯的明增强快速眼动睡眠的特性与认知功能之间的关系似乎很有前景。
